Comparative Pharmacology
Head-to-head clinical analysis: THEO 24 versus THEOPHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEO 24 versus THEOPHYL.
THEO-24 vs THEOPHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline, a xanthine derivative, acts as a non-selective phosphodiesterase (PDE) inhibitor (primarily PDE3 and PDE4), increasing intracellular cAMP and cGMP in airway smooth muscle and inflammatory cells. It also antagonizes adenosine receptors (A1, A2), stimulates endogenous catecholamine release, and may enhance histone deacetylase activity, reducing inflammation.
Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.
300-600 mg orally once daily, extended-release capsule; individualize based on serum theophylline concentration targeting 5-15 mcg/mL.
300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h
None Documented
None Documented
Clinical Note
moderateTheophylline + Gatifloxacin
"The metabolism of Gatifloxacin can be decreased when combined with Theophylline."
Clinical Note
moderateTheophylline + Rosoxacin
"The metabolism of Rosoxacin can be decreased when combined with Theophylline."
Clinical Note
moderateTheophylline + Levofloxacin
"The metabolism of Levofloxacin can be decreased when combined with Theophylline."
Clinical Note
moderateTheophylline + Trovafloxacin
Terminal elimination half-life is approximately 3–8 hours in adults (non-smokers), 4–5 hours in smokers (due to enzyme induction), and highly variable in neonates (24–36 hours) and children (1–9 hours). Half-life is prolonged in cirrhosis (up to 30 hours), heart failure, and with concomitant medications (e.g., cimetidine, erythromycin).
Terminal elimination half-life: Adults nonsmokers: 6–12 h (mean 8.7 h); adult smokers: 4–5 h; children: 3–5 h; neonates: 20–30 h; hepatic cirrhosis: up to 30 h. Half-life increases with congestive heart failure, fever, and concurrent CYP1A2 inhibitors (e.g., cimetidine, fluvoxamine).
Approximately 90% of theophylline is eliminated hepatically via metabolism (principally CYP1A2 and CYP3A4), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug is minimal (about 5%) in adults. Biliary/fecal excretion accounts for less than 1%.
Renal: 10% unchanged in adults (higher in neonates). Hepatic metabolism to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid) excreted renally; fecal excretion <5%.
Category C
Category C
Bronchodilator
Bronchodilator
"The metabolism of Trovafloxacin can be decreased when combined with Theophylline."